Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Flexus Biosciences, Inc.

2015 · Acquisition/Merger · $1.2B · Complete

Announcement Sentiment

Neutral / mixed

BMS agreed to acquire Flexus for $800M upfront plus up to $450M development milestones, gaining lead small-molecule IDO1 inhibitor F001287 plus IDO/TDO discovery program with IDO-selective, IDO/TDO dual, and TDO-selective compound libraries to expand BMS's immuno-oncology pipeline.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 10yr post-close.

Key facts

Announced Feb 23, 2015
Closed Apr 09, 2015
Deal value $1.2B
Deal type Acquisition/Merger
Therapeutic area Solid tumors (immuno-oncology)
Indications Solid tumors (immuno-oncology)
Key assets F001287 (IDO1 inhibitor)
Mechanism Small-molecule indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals